Dr Neela Patel, Chief Business Officer at Bonum Therapeutics, offers advice on how to negotiate a winning deal in biopharma that meets investors’, buyers’ and sellers’ goals. Business development (BD) is an essential ingredient to the success of early-stage companies, whether they plan to exit through M&A, IPO, or have… Read More
UK-based Contract Research Organisation (CRO) Gentronix has received a King’s Award for Enterprise after achieving triple-figure revenue growth following rapid expansion in international markets. The toxicology specialist based at Alderley Park recorded total growth of 239% in overseas earning over the past three years. In the same… Read More
BenevolentAI has announced it will be reducing headcount by around 30% and closing its US office as part of a change of focus in its business priorities. The company says it will focus on its AI-driven drug discovery collaboration and proprietary pipeline, believing these will bring… Read More
Strand Therapeutics has announced an 18% cut to its workforce, just days after the US Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to initiate a first-in-human trial of STX-001 for solid tumours. On LinkedIn the company said: “This week, Strand has… Read More
The annual Genesis conference took place at the end of 2023 in London, bringing together key opinion leaders, investors and innovators from across the life sciences sector to exchange insights, debate trends and generate deals. DDW’s Megan Thomas attended and reflects on highlights of the programme. Stacking… Read More
Arena BioWorks has launched as a biomedical research institute with a stated mission to uncover mechanisms of disease by engaging in basic biological research that will be translated into lifesaving biotech therapeutics. Arena BioWorks describes itself as a dual-purpose entity aimed at achieving social good and… Read More
1. Amgen and NVIDIA Amgen has announced plans to advance drug discovery using NVIDIA’s DGX SuperPOD-powered insights from human datasets. The NVIDIA DGX SuperPOD will be installed at Amgen’s deCODE genetics’ headquarters in Reykjavik, Iceland and will be used to build a human diversity atlas for… Read More
Centricity Research has acquired North Carolina-based Lucas Research, making it the fifth clinical research company to join Centricity since it launched in November 2021. With this acquisition, Centricity now has more than 35 clinical research sites, reaching 8.5 million geographically and ethnically-diverse patients. The company has… Read More
As the second quarter of 2023 draws to a close, DDW’s Megan Thomas reviews key updates and results from three top pharmaceutical companies. Business updates Pfizer reported second quarter 2023 revenues totalling $12.7 billion, a decrease of $15.0 billion, or 54%, compared to the prior year… Read More
The life sciences sector has seen significant M&A activity over the last few weeks. DDW’s Diana Spencer provides an overview. BioIVT acquires PrecisionMed In July BioIVT acquired biospecimens company PrecisionMed, gaining access to, reportedly, the largest private, global repository of longitudinally collected human CSF for scientific… Read More
Biogen has revealed an agreement to acquire Reata Pharmaceuticals for approximately $7.3 billion. The news follows an announcement by the company last week that it would cut around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. In its second quarter… Read More
Shares in AstraZeneca fell by 6% on July 3 when the company published the first results from its Phase III trial for datopotamab deruxtecan (Dato-DXd) and continued to fall throughout the day, though there was some recovery on July 4. It was reported that the therapy… Read More
Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs $2.5 billion in 2022, with just under 70% stemming from the US. The predictions come from analysts at Bloomberg Intelligence (BI), who believe securing broad reimbursement and supply are key, with a possible… Read More
This is the latest episode of the free DDW narrated podcast, “The impact of technology on drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Talking Tech” and “Rejuvenation biotech: Can… Read More
PerkinElmer has successfully completed the divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital. The resulting new Life Sciences and Diagnostics business will share the PerkinElmer name until a new name, brand and ticker symbol is unveiled in Q2 2023 pending shareholder… Read More
Listen to this article on the DDW Podcast: Craig Caceci, Managing Director at Terebellum, offers guidance to pharmaceutical companies that are in the position to take their drugs to market. In today’s competitive environment, a winning, fail-safe drug launch strategy is more important than ever, especially… Read More
